GoodRx Holdings annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
GoodRx Holdings Stock-Based Compensation Growth & History (GDRX)
GoodRx Holdings's stock-based compensation was $76.6M for fiscal 2025.
View full GoodRx Holdings company overviewGoodRx Holdings annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $76.6M | −$22.4M | −22.62% |
| 2024 | 2024-12-31 | $99.0M | −$5.8M | −5.53% |
| 2023 | 2023-12-31 | $104.8M | −$15.4M | −12.82% |
| 2022 | 2022-12-31 | $120.2M | −$40.2M | −25.07% |
| 2021 | 2021-12-31 | $160.5M | −$236.8M | −59.61% |
| 2020 | 2020-12-31 | $397.3M | $393.5M | +10502.75% |
| 2019 | 2019-12-31 | $3.7M | $2.0M | +112.66% |
| 2018 | 2018-12-31 | $1.8M | — | — |
GoodRx Holdings quarterly stock-based compensation
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $16.6M | −$4.8M | −22.52% |
| Q1 2026 | 2026-03-31 | $16.5M | −$2.7M | −13.90% |
| Q4 2025 | 2025-12-31 | $17.9M | −$3.0M | −14.50% |
| Q3 2025 | 2025-09-30 | $18.1M | −$8.3M | −31.32% |
| Q2 2025 | 2025-06-30 | $21.4M | −$5.2M | −19.46% |
| Q1 2025 | 2025-03-31 | $19.2M | −$5.9M | −23.60% |
| Q4 2024 | 2024-12-31 | $21.0M | −$7.8M | −27.17% |
| Q3 2024 | 2024-09-30 | $26.4M | −$6.3M | −19.19% |
| Q2 2024 | 2024-06-30 | $26.6M | $8.7M | +48.57% |
| Q1 2024 | 2024-03-31 | $25.1M | −$403,000 | −1.58% |
| Q4 2023 | 2023-12-31 | $28.8M | −$636,000 | −2.16% |
| Q3 2023 | 2023-09-30 | $32.6M | $3.6M | +12.43% |
| Q2 2023 | 2023-06-30 | $17.9M | −$13.7M | −43.42% |
| Q1 2023 | 2023-03-31 | $25.5M | −$4.7M | −15.42% |
| Q4 2022 | 2022-12-31 | $29.4M | −$3.9M | −11.62% |
| Q3 2022 | 2022-09-30 | $29.0M | −$10.9M | −27.37% |
| Q2 2022 | 2022-06-30 | $31.6M | −$9.0M | −22.23% |
| Q1 2022 | 2022-03-31 | $30.1M | −$16.4M | −35.20% |
| Q4 2021 | 2021-12-31 | $33.3M | −$252.8M | −88.37% |
| Q3 2021 | 2021-09-30 | $40.0M | −$66.9M | −62.59% |
| Q2 2021 | 2021-06-30 | $40.7M | $38.6M | +1817.77% |
| Q1 2021 | 2021-03-31 | $46.5M | $44.3M | +2005.25% |
| Q4 2020 | 2020-12-31 | $286.1M | — | — |
| Q3 2020 | 2020-09-30 | $106.9M | — | — |
| Q2 2020 | 2020-06-30 | $2.1M | — | — |
| Q1 2020 | 2020-03-31 | $2.2M | — | — |
GoodRx Holdings stock-based compensation trends
Over the last five fiscal years, GoodRx Holdings's stock-based compensation decreased from $397.3M to $76.6M, a change of −$320.7M. The latest reported quarter, Q2 2026, shows $16.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review GoodRx Holdings source filings ↗